M
Matthias Bergmann
Researcher at Ludwig Maximilian University of Munich
Publications - 1
Citations - 1758
Matthias Bergmann is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Obinutuzumab & Ofatumumab. The author has an hindex of 1, co-authored 1 publications receiving 1641 citations.
Papers
More filters
Journal ArticleDOI
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek,Kirsten Fischer,Günter Fingerle-Rowson,Anna-Maria Fink,Raymonde Busch,Jiří Mayer,Manfred Hensel,Georg Hopfinger,G D Hess,U. Von Grünhagen,Matthias Bergmann,John Catalano,Pier Luigi Zinzani,Federico Caligaris-Cappio,John F. Seymour,Alain Berrebi,Ulrich Jäger,Bruno Cazin,Marek Trneny,Anne Westermann,Clemens M. Wendtner,Barbara Eichhorst,Peter Staib,Andreas Bühler,Dirk Winkler,Thorsten Zenz,S Böttcher,Matthias Ritgen,Myriam Mendila,Michael Kneba,Hartmut Döhner,Stephan Stilgenbauer +31 more
TL;DR: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia, and the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytes.